Track records

Some of our major success stories include:

• Sussex collaborator company ReViral to be acquired by Pfizer, funded by a Seeding Drug Discovery Award from the Wellcome Trust
• discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion
• Enterprise Therapeutics’ 1st in class TMEME16A potentiator programme, for cystic fibrosis, acquired by Roche
• Prof Tony Moore span out his company AlternOx in 2020. AlternOx develops novel treatments for drug resistant species of fungi with implication for plant and human health
• major strategic partnership with Sophion Bioscience
• 113-Botanicals pledge substantial funding (including iCASE EPSRC award)
• GlaxoSmithKline, a legacy AMPA project now funded by WT SDDA
• AstraZeneca screening partnerships to prosecute novel targets.